The Pharmacy Times® Pneumococcal Resource Center is a comprehensive resource for clinical news and expert insights for any infection caused by the bacteria Streptococcus pneumoniae, or pneumococcus.
October 21st 2024
Data presented at IDWeek also showed greater disease-prevention effects in the community with PCV21 compared with prior pneumococcal vaccines.
Influenza Prevention in the At-Risk Adult Population and the Pharmacist's Role in an Evolving Influenza Vaccin...
1.25 Credits / Immunization, Infectious Diseases
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Navigating the HIV Treatment Frontier: Equipping Managed Care Professionals With Strategies for Innovation, Ac...
1.5 Credits / HIV/AIDS, Infectious Diseases
View More
Pneumococcal Disease Prevention for Older Adults and the Pharmacist’s Role in an Evolving Vaccine Landscape
1.0 Credit / Immunization, Infectious Diseases
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
Duration of Vancomycin Reduced Through Education of Prescribers, Utilization of MRSA PCR Nasal Swab
December 8th 2020The objective of the study was to develop a method for de-escalation of intravenous (IV) vancomycin in patients receiving vancomycin with at least 1 other antibiotic appropriate for the treatment of community-acquired pneumonia (CAP).
Read More
Study: New 15-Valent Pneumococcal Conjugate Vaccine Meets Immunogenicity and Safety Objectives
July 2nd 2020Results from 2 initial phase 3 studies evaluating an investigational 15-valent pneumococcal conjugate vaccine were recently released, assessing its immunogenicity, safety, and tolerability.
Read More
Antibiotic Granted FDA Approval for Expanded Indication to Include Certain Pneumonia
June 5th 2020The combination of imipenem-cilastatin and relebactam was previously approved by the FDA to treat patients with complicated urinary tract infections and complicated intra-abdominal infections who have limited or no alternative treatment options.
Read More
Robust Responses Found in 20-Serotype Pneumococcal Vaccine Trial
April 17th 2019The study presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam, Netherlands was a phase 2 randomized, active-controlled, double-blinded trial (N=444). All participants were ages 60 to 64 years.
Read More